Nursing Perspectives on Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Guest Editor
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The supplement and associated publication costs were funded by Onyx Pharmaceuticals, Inc. Fishawack Communications, Inc., provided medical writing and editorial assistance, supported by Onyx Pharmaceuticals.
Review Article
Relapsed or Relapsed/Refractory Multiple Myeloma
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
Read MorePrescriber's Corner
Carfilzomib
J. Michael Vozniak, PharmD, BCOPRead MoreReview Article
The Side Effect Profile of Carfilzomib: From Clinical Trials to Clinical Practice
Laura McBride, RN, BSN, OCN®, CCRP, and Christine O. Samuel, RN, BSN, OCN®, CCRPRead MoreGrand Rounds
Treatment of Patients With Multiple Myeloma: A Relapsed and Refractory Case Study
Sandra E. Kurtin, RN, MS, AOCN®, ANP-CRead MoreReview Article
Treatment With Carfilzomib: A Promising Future for Multiple Myeloma
Donna Catamero, ANP-BC, OCN®, CCRC, and Charise Gleason, MSN, ANP, AOCNP®Read More